other material
confidence high
sentiment negative
materiality 0.75
Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO
Harvard Apparatus Regenerative Technology, Inc.
- Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.
- HBIO to pay $4M of costs; Biostage will issue $4M of 8% convertible preferred stock.
- Preferred converts automatically upon qualified offering (e.g., NASDAQ uplisting or $4M+ private placement) at offering price.
- Remaining ~$1.7M in costs and future legal expenses still payable by Biostage or indemnified to HBIO.
- Neither party admits liability; claims dismissed with prejudice.